Mind Medicine (MindMed) Inc. (MNMD)
NASDAQ: MNMD · Real-Time Price · USD
5.65
-0.13 (-2.17%)
At close: Apr 21, 2025, 4:00 PM
5.69
+0.05 (0.80%)
After-hours: Apr 21, 2025, 5:01 PM EDT

Company Description

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.

Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) logo
Country United States
Founded 2019
Industry Biotechnology
Sector Healthcare
Employees 74
CEO Robert Barrow

Contact Details

Address:
One World Trade Center, Suite 8500
New York, New York 10007
United States
Phone 212 220 6633
Website mindmed.co

Stock Details

Ticker Symbol MNMD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001813814
CUSIP Number 60255C109
ISIN Number CA60255C8850
SIC Code 2833

Key Executives

Name Position
Robert Barrow Chief Executive Officer and Director
Dr. Daniel Rollings Karlin M.A., M.D. Chief Medical Officer
Dr. Scott M. Freeman M.D. Co-Founder and Clinical Advisor
Leonard Latchman Co-Founder
Peter Mack Senior Vice President of Pharmaceutical Development and Operations
Carrie F. Liao CPA, CGMA Vice President and Chief Accounting Officer
Mark R. Sullivan J.D. Chief Legal Officer and Corporate Secretary
Stephanie Fagan Chief Corporate Affairs Officer
Dr. Gregg Pratt Ph.D. Chief Regulatory and Quality Assurance Officer
Matthew Wiley Chief Commercial Officer

Latest SEC Filings

Date Type Title
Apr 21, 2025 8-K Current Report
Apr 15, 2025 8-K Current Report
Mar 25, 2025 144 Filing
Mar 25, 2025 144 Filing
Mar 25, 2025 144 Filing
Mar 25, 2025 144 Filing
Mar 6, 2025 10-K Annual Report
Mar 6, 2025 8-K Current Report
Feb 5, 2025 SCHEDULE 13G/A Filing
Jan 30, 2025 8-K Current Report